In the periphery, elevated adenosine levels present in the microenvironment of tumors lead to a suppressed immune response, to shift the T cell response away from an aggressive state capable of attacking tumors.6 Increasing evidence supports the use of AR antagonists in cancer treatment, either with selectivity for the A2AAR alone or with dual selectivity for the A2AAR and A2BAR. Here, AR is linked to cancer.